Qian, Yi
Arellano, Jorge
Gatta, Francesca
Hechmati, Guy
Hauber, A. Brett
Mohamed, Ateesha F.
Bahl, Amit
von Moos, Roger
Body, Jean-Jacques
Funding for this research was provided by:
Amgen
Article History
Received: 1 July 2016
Accepted: 1 June 2018
First Online: 3 July 2018
Ethics approval and consent to participate
: This study was approved by the IRB of the Office of Research Protection and Ethics at RTI International (the responsible study organisation) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Participants gave their informed consent prior to their inclusion in the study.
: GH, JA, FG and YQ are employed by Amgen and own stock. ABH is an employee of RTI Health Solutions and has no conflict of interest. AFM was employed at RTI Health Solutions during the study and has no conflict of interest. AB has received honoraria for participating in Advisory Boards from Amgen, Sanofi, Astellas, Roche, Novartis and Bayer. RvM has received research grants from Amgen, Roche and Merck. He has participated in Advisory Boards for Amgen, Roche, Novartis, Merck, MSD, and Eli Lilly. He has received speaking honoraria from Amgen and GSK. JJB has received speaking honoraria and consulting fees from Amgen and Novartis. The authors declares that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.